Background. Multiple genes underlying focal segmental glomerulosclerosis (FSGS) and/or steroid-resistant nephrotic syndrome (SRNS) have been identified, with the recent inclusion of collagen IV mutations responsible for Alport disease (AD) or thin basement membrane nephropathy (TBMN). We aimed to investigate the distribution of gene mutations in adult patients with primary FSGS/SRNS by targeted next generation sequencing (NGS). Methods. Eighty-one adults from 76 families were recruited; 24 families had a history of renal disease. A targeted NGS panel was designed and applied, covering 39 genes implicated in FSGS/SRNS including COL4A3-5. Results. Confirmed pathogenic mutations were found in 10 patients (6 with family history) from 9 families (diagnostic rate 12%). Probably pathogenic mutations were identified in an additional six patients (combined diagnostic rate 20%). Definitely pathogenic mutations were identified in 22% of patients with family history and 10% without. Mutations in COL4A3-5 were present in eight patients from six families, representing 56% of definitely pathogenic mutations, and establishing a diagnosis of AD in six patients and TBMN in two patients. Collagen mutations were identified in 38% of families with familial FSGS, and 3% with sporadic FSGS, with over half the mutations occurring in COL4A5. Patients with collagen mutations were younger at presentation and more likely to have family history, haematuria and glomerular basement membrane abnormalities. Conclusions. We show that collagen IV mutations, including COL4A5, frequently underlie FSGS and should be considered, particularly with a positive family history. Targeted NGS improves diagnostic efficiency by investigating many candidate genes in parallel.
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I N T R O D U C T I O N
Focal segmental glomerulosclerosis (FSGS) is not a single entity, but a clinico-pathological diagnosis, which encompasses a spectrum of underlying disorders. It is characterized by the presence of proteinuria and eponymous findings on renal biopsy. FSGS has a large overlap with the paediatric diagnosis of steroid-resistant nephrotic syndrome (SRNS), for which FSGS is the most common biopsy finding [1] . Mutations in several podocyte genes are causative, with an estimated 8-14% of adult onset FSGS explained by podocyte gene mutations [2, 3] .
Alport disease (AD) is characterized by haematuria and progressive renal impairment, often in association with sensorineural hearing loss, anterior lenticonus and retinopathy. Biopsy appearances are diverse, and often non-diagnostic [4] . Electron microscopy (EM) changes include thinning and thickening of the glomerular basement membrane (GBM), splitting and lamellation, which are neither completely sensitive nor specific [4, 5] . Immunofluorescence studies for the absence of the collagen alpha 5 chain can improve diagnostic accuracy [5] , but are not 100% sensitive, nor routinely available in clinical practice.
COL4A5 mutations with X-linked inheritance are responsible for ∼85% of AD [6, 7] . Homozygous or compound heterozygous COL4A3 and COL4A4 mutations cause autosomal recessive AD [8] . Heterozygous COL4A3 and COL4A4 mutations are found in 40% of patients with thin basement membrane nephropathy (TBMN) and have also been proposed as a cause of autosomal dominant AD [9] .
Collagen mutations causing AD have recently been found in FSGS in a number of publications, including a homozygous COL4A4 mutation in a patient with SRNS uncovered by targeted next generation sequencing (NGS) [10] , a COL4A5 mutation found in a multiplex kindred with familial FSGS by exome sequencing [11] , and other similar reports [12, 13] . Earlier publications demonstrated the development of FSGS in a proportion of cases with TBMN due to heterozygous COL4A3/4 mutations [14] [15] [16] [17] . A recent series of 70 families with familial FSGS revealed COL4A3/4 mutations in 10% [18] . COL4A3 mutations were also found in 5 of 40 Chinese families with FSGS (12.5%), and in one of 50 sporadic cases [19] . Furthermore, COL4 mutations have been proposed as modifier mutations in FSGS [20] .
The collagen genes COL4A3-5 are very large; thus sequencing by conventional methods is both time-consuming and expensive. NGS can be faster and more efficient, by allowing the simultaneous sequencing of multiple genes for a fraction of the cost of conventional sequencing. NGS has already been applied successfully to patients with AD [9, 21] .
In recent years, several targeted NGS panels have been used to investigate SRNS [10, 22] . The most comprehensive panel included 27 SRNS genes, and identified disease-causing mutations in 29.5% of 1783 families with disease onset under age 25 years [22] . Only small numbers of patients have been included in targeted adult FSGS panels [13] .
The list of genes implicated in the development of FSGS is growing rapidly. Therefore targeted panels need to be updated continuously [23] [24] [25] [26] . To date, there has been no NGS panel testing an extensive list of genes in a large adult cohort with FSGS. It also remains unclear to what extent collagen mutations underlie FSGS, although two very recent publications [18, 19] provide estimates for COL4A3/4 mutations in familial FSGS. To uncover the distribution of disease-causing gene mutations in an adult FSGS/SRNS population, we designed an NGS panel covering 39 genes, and applied this panel to 81 adult patients with FSGS or SRNS.
M AT E R I A L S A N D M E T H O D S

Patient ascertainment
Eighty-one patients with primary FSGS or SRNS registered with the Wessex Kidney Centre (catchment population 2.3 million) were recruited, after prioritizing those with a family history (FHx) of renal disease. Clinical data were recorded from patient interviews and clinical records.
Ethics
All study procedures had full UK Research Ethics Committee and local Research and Development approval (REC reference 11/SC/0111), and adhered to the Declaration of Helsinki.
Gene panel design A gene panel containing 39 genes was designed on the Illumina TruSeq Custom Amplicon platform using the vendor DesignStudio software. Gene coverage was manually optimized. The genes for inclusion on the panel (Table 1) were chosen based on a comprehensive literature review and information from the Human Gene Mutation Database (HGMD) Professional 2013.1 and 2013.3 [27] .
In vitro methods Genomic DNA extraction from saliva was performed by Oragene kit (DNA Genotek, Ontario, Canada), and from whole blood by QIAamp DNA Blood Midi kit (Qiagen, Venlo, The Netherlands) or the salting out method [28] . The TSCA kit was processed and sequenced on the MiSeq system (Illumina, San Diego, CA, USA) as per the manufacturer's instructions. A sample tracking panel was utilized to ensure final data provenance [29] . Identified pathogenic variants with a read depth ≤80 were confirmed by Sanger sequencing.
In silico data processing Raw NGS reads were subjected to initial quality check using FastQC [30] and aligned to reference genome GRCh37 (hg19) using NovoalignMPI v3.01.00 [31] ; coverage statistics were collated with BEDTools v2.17 [32] . Variants deviating from the reference sequence were called individually using SAMtools v0.1.19 [33] , and filtered with VCFtools v0.1.12 [34] . Called variants were annotated with variant coding effects, minor allele frequencies (MAF) for populations of European descent from the 1000 Genomes Project (1KG) [35] and Exome Sequencing Project (ESP) [36] , and predictive metrics of deleteriousness, including PolyPhen-2 [37] , with ANNOVAR v2013Aug23 [38] .
Splicing variants within 10 base pairs of an intron/exon boundary were scored using a Maximum Entropy (MaxEnt) model [39] . A difference cut-off in MaxEnt score of |>3| was used to predict disruption of pre-mRNA splicing [40] .
Assignment of pathogenicity categories
Recommendations by the American College of Medical Genetics (ACMG) [41] were followed to allocate variants into the categories 'definitely pathogenic', 'probably pathogenic' and 'possibly pathogenic'. 'Definitely pathogenic' mutations were listed in HGMD, consistent with the phenotype, and individually assessed to establish the strength of evidence for pathogenicity in the literature. 'Probably pathogenic' mutations included novel splice site, frame shift and nonsense mutations, and mutations listed as disease-causing in HGMD with insufficient or conflicting evidence in the literature to determine their definite pathogenicity. 'Possibly pathogenic' mutations consisted of nonsynonymous mutations with an MAF <0.05. Mutation zygosity had to match its known pattern of inheritance, and be present in all affected relatives in the panel to be considered disease-causing.
Clinical parameters associated with pathogenic mutations Clinico-pathological parameters were compared between patients with pathogenic collagen mutations and the remaining cohort. Statistical significance was determined by the χ 2 , Fisher's exact test, or Mann-Whitney U test as appropriate, using SPSS version 21 (IBM, Armonk, NY, USA).
R E S U LT S
Data quality A total of 98.9% of the coding region was targeted successfully across 39 genes (Table 1) . Following sequencing and alignment, >94% of the targeted region was covered to a depth of at least 10×, with a mean depth of >300× (Supplementary Table S1 ).
Patients
Eighty patients with FSGS and one with SRNS were recruited into the study ( Table 2 ). The cohort included nine individuals from within the region belonging to four families. To the best of our knowledge, the remaining individuals were unrelated, resulting in 76 independent families. All but two patients were Caucasian (one Black African and one Asian). The diagnosis of FSGS was based on eponymous biopsy findings in combination with proteinuria, except in five patients, where no biopsies were taken, and two patients with minimal change disease on biopsy. Their diagnosis of FSGS was supported by biopsies in similarly affected relatives and/or the clinical picture. A diagnosis of 'familial FSGS', requiring the diagnosis of FSGS in at least one relative, was established in 12 individuals from 8 families.
Called variants
Five hundred and sixty-two on-target variants across the 39 genes were identified in the 81 patients. After filtering for functional effects and MAF, 266 variants remained ( Figure 1 ). Seventeen definitely pathogenic variants, 5 probably pathogenic variants [39] (Table 3 ) and 242 possibly pathogenic variants (Supplementary Table S2 ) were identified. The participantcentric Table 4 shows only those definitely or probably pathogenic variants that occurred in the zygosity reported to be disease-causing. As indicated in Tables 3 and 4 , pathogenic variants with a read depth ≤80 were confirmed by Sanger sequencing.
Diagnostic rates. Definitely pathogenic mutations were found in 12 patients from 10 of 76 families. In order to establish diagnostic rates for a pure adult FSGS/SRNS cohort, we excluded a family with suspected AD from the statistics, leaving 75 families. Thus we achieved molecular diagnoses in 12% of families and 13% of the case series (Table 5 ). Definitely and probably pathogenic mutations combined were identified in 16 patients from 15 families, giving a diagnostic rate of 20%. All genes for FSGS and AD listed in HGMD 2013.1 and 2013.3 were included, with the exception of COL4A6, excluded due to size limitations on the panel, and the fact that X-linked AD with leiomyomatosis only occurs in the presence of contiguous deletions of COL4A5 and COL4A6. All genes from an NGS panel for SRNS [10] and a recent review of FSGS genes [25] were included. Additional genes were selected from another recent NGS panel [13] if genes were linked to AD or FSGS in the literature. Recently identified candidate genes for FSGS were also included [23, 24] , even if their role in FSGS was still speculative, and not fully confirmed. CHR, chromosome.
Diagnostic rates for patients with and without FHx, and according to the age of disease onset are shown in Table 5 .
Patients with collagen mutations. Eight participants from six families with disease-causing collagen mutations were identified (Table 6) , including one family with suspected AD (F2). Excluding this family, collagen mutations represented 56% of all definitely pathogenic mutations. The discovered COL4 mutations confirmed the diagnosis of AD in two patients (F2 brother and sister), and changed it to AD in four (F1 mother and son, I1 and I3) and TBMN in two patients (I2 and I6). All participants had heavy proteinuria, resulting in nephrotic syndrome in I1. There was no documented microscopic haematuria in F1 mother, I1 (male) and I3 (female). Only one participant presented with hearing loss (F2 brother). In two others, hearing loss developed post-transplantation and was attributed to external factors. Ophthalmic tests are only documented in I1 and were normal. Light microscopy showed FSGS in all biopsied participants, with the exception of F2 sister (normal light microscopy). As shown in Table 6 , F1 mother's first EM was normal, the second revealed GBM lamellation possibly compatible with AD, but she had no associated clinical features or FHx at the time. The EM in F1 son was not diagnostic, but showed widespread podocyte foot process fusion, lamellation and splitting of the GBM. Clinical testing for AD was arranged at the time, but not completed. The two participants with single COL4A3/4 mutations (I2 and I6) had microscopic haematuria (with a FHx in I2), nephrotic range proteinuria, and FSGS on light microscopy. EM in I2 was normal.
Patients with other confirmed pathogenic mutations. Pathogenic mutations in INF2 and CD2AP causing autosomal dominant disease were found in patients I4, and I7; both had biopsy-proven FSGS. Compound heterozygosity for two NPHP4 mutations in I6 with sporadic biopsy-proven FSGS and nephrotic range proteinuria changed his diagnosis to nephronophthisis. The MYH9 mutation M1651T in I8 with sporadic FSGS and intermittent macroscopic haematuria at presentation causes May Hegglin anomaly, characterized by platelet anomalies with the possible development of renal failure. There was no clinical suspicion of this diagnosis prior to genetic testing, and no platelet abnormalities were noted, but the clinical picture was confused by recurrent bleeding on anticoagulants, requiring multiple blood transfusions.
Patients with probably pathogenic mutations. Probably pathogenic splice-site mutations in WT1, INF2 and NXF5 were discovered in three individuals (I12-I14), all with biopsyproven FSGS. We took the conservative approach of classifying the nonsynonymous mutations in LAMA5 in I9 and I10, and in ACTN4 in I11 as probably pathogenic, instead of pathogenic despite their listing in HGMD, due to either conflicting or insufficient evidence in the literature regarding their pathogenicity.
Mutations in families.
No reported pathogenic mutations were identified in two of the four families on the panel. F4 sisters 1 and 2 both have the novel LAMB2 variant D181N, which would be expected to be recessive. No common mutations were found for F3 father, daughter 1 and daughter 2. Apart from two pathogenic COL4A3 mutations, F2 brother and sister also share the ACTN4 variant R310Q and the APOL1 variant S324G.
Clinical characteristics associated with pathogenic mutations. Clinical and histological features were analysed for patients with pathogenic collagen mutations, compared with the remaining patients (Table 7) . Differences in gender, proteinuria, age at renal replacement therapy (RRT), RRT requirement, renal transplantation and biopsy findings were not significantly different. COL4 mutation patients were more likely to have FHx, haematuria, GBM abnormalities and younger age at presentation.
D I S C U S S I O N
We designed a customized NGS panel for the investigation of FSGS/SRNS, which is the first comprehensive FSGS gene panel in an adult cohort. Targeted panels have been recognized as a promising approach in the investigation of FSGS [42] . We have shown that this technique works well with excellent coverage of the targeted genes after manual optimization, and a high diagnostic rate. We resolved 12-20% of all FSGS/SRNS cases. This represents 22-26% of families with family history and 10-19% of those without. We solved 13-20% of adult onset Clinical information on all study participants. RRT, renal replacement therapy; PCR, protein creatinine ratio.
cases, which is higher than the previously reported 8-14% [2, 3] , and explained by our use of NGS allowing the testing of a comprehensive gene panel.
Of strong clinical relevance is the frequency with which COL4 mutations were found to underlie FSGS. Pathogenic COL4 mutations were discovered in five of nine families (56%) with a definitely pathogenic gene mutation, and 7% of families in the cohort, representing the highest prevalence of any mutation. They were found in 38% of families with familial FSGS (3/8), and 3% of sporadic FSGS/SRNS (2/67). AD or TBMN had only been suspected in one family (F2) not included in the statistics.
Our prevalence of COL4 mutations in familial FSGS is higher than the recently reported 10-12.5% [18, 19] , which is likely explained by our inclusion of COL4A5, where over half of our COL4 mutations occurred. This is more consistent with the mutation distribution in AD [7] . Our cohort included more patients with sporadic than familial FSGS, thus also giving an estimated prevalence of COL4 mutations in sporadic FSGS.
The simultaneous sequencing of 36 podocyte genes allowed us to rule out potential modifier mutations in NPHS1/2. The ACTN4 variant R310Q in F2 brother and sister is thought to predispose to FSGS [43, 44] and may have acted as a modifier.
Theoretically others could have been missed by less than complete coverage and the unknown effect of novel variants.
We established six new diagnoses of AD in our FSGS cohort. AD can be difficult to diagnose due to variations in diagnostic features, both clinical and histological [45] [46] [47] . Diagnostic criteria for AD have been published recently [48] . They rely on the presence of (familial) haematuria with or without renal impairment, in combination with either characteristic EM biopsy changes or specified COL4 mutations-which established the diagnosis in all patients in our cohort. FSGS has been found to be the most common misdiagnosis in female patients with X-linked AD [45] . In these cases it can be difficult to distinguish biopsy changes of AD mimicking FSGS (called phenocopy) from a development of secondary FSGS.
There is evidence that FSGS occurring in our patients with AD is more likely to represent FSGS phenocopy than merely the late development of secondary FSGS. The first biopsy per family was taken 0-3 years after presentation when the excretory renal function was still (near) normal. GBM thickness was largely within normal limits in all four EMs, with normal GBM appearance on F1 mother's first biopsy and FSGS on light microscopy. Phenocopy is likely to have developed by chance F I G U R E 1 : Filtering steps of the reported on-target variants. *The 1000 Genomes Project (1KG) and Exome Server Project (ESP) are large genomic databases including populations with European ancestry. Variants with a frequency of >5% in these databases were excluded from further study as they are likely to be common population polymorphisms with no significant functional consequences. **Variants found to be common in our own genetic non-disease database of unrelated whole-exome sequenced individuals (n = 292).
#
Variants with an MAF in the cohort of >5% were excluded as they were likely to represent common local population polymorphisms or batch effects (artefacts). Listed in the HGMD, but inconsistencies in literature for causality [13, 43] . Confirmed by Sanger sequencing as read depth ≤80. While some unrelated individuals share pathogenic mutations, we are unable to discern reliably whether these are from a common source, or have arisen independently, due to the punctuate nature of the targeted sequencing data. c Biopsy proven.
d
Excluded from statistics.
consistent with AD's diverse biopsy features, or there could be as yet unknown modifying factors. Relevantly, the clinical features of the patients with COL4 mutations were atypical for AD. Three patients (one male, two female) with COL4A5 mutations had no documented haematuria. The absence of haematuria is reported in 5% of females [47] , but 0% of males with X-linked AD [46] . It is possible that haematuria was present intermittently in male I1, but missed at clinical sampling, with his clinical records being incomplete following transfer from another unit. Hearing loss developed late in two of three males, and was not present in any female. This is compatible with 90% of males and 10% of females developing hearing loss before the age of 40 years [46, 47] . The severe phenotype in F1 mother and female I5 with progression to ESRD occurs in 15% of female carriers [47] , and is likely due to skewed X-inactivation [49] .
Several pathogenic mutations were encountered in other patients in CD2AP, INF2, LAMA5 and ACTN4, reported to cause autosomal dominant FSGS of adult onset. We are only the second group to describe mutations in LAMA5 in FSGS [13] , with mouse models demonstrating LAMA5's role in the formation and maintenance of the glomerular filtration barrier [50, 51] . The mutation p.G6358R found in two of our patients was also identified by a previous targeted NGS panel [13] . Further work is needed to confirm the exact role of LAMA5 in FSGS.
The discovery of two NPHP4 mutations changed the diagnosis of I6 from FSGS to nephronophthisis, also known to be associated with biopsy findings of FSGS [52] . MYH9 mutations Diagnostic rates for the total cohort, patients with and without family history, and according to age of onset are shown for definitely pathogenic mutations alone, and for definitely pathogenic mutations in combination with probably pathogenic mutations. 
O R I G I N A L A R T I C L E
C o l l a g e n I V m u t a t i o n s i n a d u l t F S G S causing May Hegglin anomaly can present with features similar to AD [53] , as was the case in I8. Assigning variants to the category 'probably pathogenic' is fraught with difficulty [41] . The probably pathogenic splice-site mutations we identified in INF2, NXF5 and WT1 have a high ΔMaximal Entropy score, which indicates a high probability of disrupting canonical splicing [40] . One variant in female I12 occurred in the same position as a published splicing change in WT1 [54] , known to cause isolated SRNS in females, and Frasier syndrome in males [55] . Without extensive functional studies, we cannot prove if all altered splice products are definitely pathogenic. The absence of a family history in some patients with presumed dominant pathogenic mutations may be explained by de novo mutations, incomplete penetrance, or a false-negative family history.
We have performed confirmatory Sanger sequencing for all pathogenic variants with read depths below 80, confirming the validity of our NGS data, since targeted NGS has been shown to be equally as reliable as conventional sequencing for read depths above 30 [56] . Before any variants are reported back to participants, fresh blood samples will be sent to an approved National Health Service (NHS) laboratory for confirmatory sequencing to meet current diagnostic standards.
By comparing patient and biopsy characteristics between participants with and without pathogenic or collagen mutations, we demonstrated that these features poorly predict the underlying pathology. As could be expected, the presence of a positive FHx and younger age at presentation make a genetic aetiology more likely. When haematuria, hearing and GBM abnormalities are present, this can suggest an underlying COL4 mutation. Our case histories confirm that EM can raise suspicion and guide genetic testing, and should become routine practice in all cases of FSGS [12] . A normal EM, however, should not give false reassurance as the typical changes have been found in only ∼60% of AD [5] .
The discovery of gene defects can have significant benefits for patients and their relatives, including genetic counselling, screening, avoiding unnecessary immunosuppression and slowing the progression of renal disease through early treatment, with known benefits of early renin-angiotensin system blockade in AD [57, 58] . The risk of graft loss in renal transplantation can be predicted as very low, due to disease recurrence for patients with podocyte mutations [59] or anti-GBM disease in AD [60] .
Our targeted NGS panel produces fast, affordable and reliable results, verified by confirmatory sequencing. The cost was approximately €250 per participant for all 39 genes, compared with conventional sequencing costs of €1000 for a single collagen gene. Limitations of the technique are the poor coverage of intronic regions (also missed by conventional sequencing), and being restricted to genes previously associated with the disease. Furthermore, the interpretation of novel variants remains challenging. We have chosen a conservative approach likely to under-diagnose pathogenic variants, rather than risk over-diagnosis. The identified 242 possibly pathogenic variants are likely to contain further disease-causing mutations and non-functional polymorphisms. This distinction cannot be clarified without extensive functional studies. The above reasons combined can explain why we did not identify pathogenic mutations in all of the investigated cases with family history.
In summary, NGS, as a targeted panel or whole exome sequencing, is an ideal approach for the genetic testing of FSGS with multiple possible underlying aetiologies. We have demonstrated that not only COL4A3/4, but also COL4A5 mutations should be considered in patients with FSGS, especially in the presence of a positive FHx, even if clinical and biopsy features are atypical.
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